Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog cytarabine

Scientific Reports
Olga RechkoblitAneel K Aggarwal

Abstract

Cytarabine (AraC) is an essential chemotherapeutic for acute myeloid leukemia (AML) and resistance to this drug is a major cause of treatment failure. AraC is a nucleoside analog that differs from 2'-deoxycytidine only by the presence of an additional hydroxyl group at the C2' position of the 2'-deoxyribose. The active form of the drug AraC 5'-triphosphate (AraCTP) is utilized by human replicative DNA polymerases to insert AraC at the 3' terminus of a growing DNA chain. This impedes further primer extension and is a primary basis for the drug action. The Y-family translesion synthesis (TLS) DNA polymerase η (Polη) counteracts this barrier to DNA replication by efficient extension from AraC-terminated primers. Here, we provide high-resolution structures of human Polη with AraC incorporated at the 3'-primer terminus. We show that Polη can accommodate AraC at different stages of the catalytic cycle, and that it can manipulate the conformation of the AraC sugar via specific hydrogen bonding and stacking interactions. Taken together, the structures provide a basis for the ability of Polη to extend DNA synthesis from AraC terminated primers.

References

Jun 28, 1988·Biochemistry·T Mikita, G P Beardsley
Sep 15, 1982·Biochemical Pharmacology·P P MajorD W Kufe
Oct 24, 1997·Advances in Cancer Research·S Grant
Jul 14, 1999·Cell Biochemistry and Biophysics·F W PerrinoS Harvey
Mar 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Sean J JohnsonLorena S Beese
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Jun 15, 2005·Annual Review of Biochemistry·Satya PrakashLouise Prakash
Apr 11, 2006·Molecular Cancer Research : MCR·Yih-wen ChenKai-ming Chou
Apr 18, 2006·Structure·Vinod K BatraSamuel H Wilson
May 4, 2007·DNA Repair·Miguel Garcia-DiazThomas A Kunkel
Aug 1, 2007·Journal of Applied Crystallography·Airlie J McCoyRandy J Read
Sep 1, 2009·Nature Structural & Molecular Biology·Michael K SwanAneel K Aggarwal
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Paul D AdamsPeter H Zwart
Jun 26, 2010·Nature·Christian BiertümpfelWei Yang
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Martyn D WinnKeith S Wilson
May 9, 2012·Nature Structural & Molecular Biology·Ajay UmmatAneel K Aggarwal
Jul 13, 2012·Nature·Teruya NakamuraWei Yang
May 1, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ye ZhaoWei Yang
Dec 3, 2014·Clinical Lymphoma, Myeloma & Leukemia·Tapan M KadiaHagop M Kantarjian
Jun 6, 2016·Trends in Cell Biology·Scott A LujanThomas A Kunkel
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor
Jul 14, 2018·Current Opinion in Structural Biology·Rinku JainOlga Rechkoblit

❮ Previous
Next ❯

Citations

Dec 12, 2018·Current Genetics·Narottam AcharyaPremlata Kumari
Oct 14, 2020·Biochemistry. Biokhimii︠a︡·E S ShilkinA V Makarova

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

PHENIX
CCP4
Coot
HKL2000

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.